Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | PKM | P14618 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | PKLR | P30613 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16083994 | 0.92 | PKLR (0.66) | TP53POLBTDP1PKMALDH1A1 | |
| SCHEMBL15713354 | 0.79 | PKLR (0.83) | PKMALDH1A1LMNAPKLR | |
| SCHEMBL15713378 | 0.79 | PKLR (0.55) | PKMLMNAPKLRMEN1KMT2A | |
| SCHEMBL15713606 | 0.78 | PKLR (0.81) | PKMALDH1A1PKLRSMN1; SMN2MAPK1 | |
| SCHEMBL15713346 | 0.78 | PKLR (0.82) | PKLR | |
| SCHEMBL7505784 | 0.78 | PKM (1.00) | TP53POLBTDP1PKMALDH1A1 | |
| SCHEMBL15713609 | 0.76 | PKLR (0.63) | PKMALDH1A1PKLR | |
| SCHEMBL15713683 | 0.76 | PKLR (0.67) | PKMALDH1A1PKLRSMN1; SMN2MAPK1 | |
| SCHEMBL15713675 | 0.76 | PKLR (0.63) | PKMALDH1A1PKLRSMN1; SMN2MAPK1 | |
| SCHEMBL15713347 | 0.76 | PKLR (0.83) | POLBALDH1A1PKLRSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458132-B2 | Therapeutic compounds and compositions and their use as PKM2 modulators | AGIOS PHARMACEUTICALS, INC (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150307473-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC (US) | 2015-10-29 | — | — | US | disclosed |
| WO-2014074848-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2014-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307473-A1 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS AND THEIR USE AS PKM2 MODULATORS | PDK1, PDK2, PDK3 | TP53 1030/4885POLB 2468/4885TDP1 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.